ALL-IN-ON-GREEN
12.12.2022 07:01:35 CET | Business Wire | Press release
At least 70 cities in Europe can now prevent huge amounts of waste from ending up in the sea. This has been demonstrated in the city of Aarhus in Denmark, where the robot SeaProtectorOne, made by All In On Green, collected over 100,000 pieces of waste from the city’s river in just 20 months. The technology thus shows how much pollution the city is otherwise sending into the marine environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221211005006/en/
Many tonnes of waste flow into the sea from the world’s rivers: A Danish robot minimises this pollution (Photo: Business Wire)
Once waste enters the oceans, removing it is extremely difficult. This is why a Danish robotics invention is tackling the problem before it happens. The robot SeaProtectorOne is installed at the river mouth in Aarhus, where the river flows into the harbour and wider sea. The robot collects the waste—things like plastic cups, facemasks and pizza boxes—before it pollutes the sea. At the same time, it allows boats and other marine vessels to pass by.
SeaProtectorOne could also limit sea pollution from rivers in at least 70 other cities in Europe. This potential has been shown by thorough studies of the cities’ local conditions carried out by the team that has developed SeaProtectorOne. Kim Gulvad Svendsen, COO, Aarhus Municipality, readily shares his positive experience with this new weapon in the fight to prevent sea pollution.
“After the trial period, we were surprised at just how effective the robot was and by how much waste – especially plastic – it removed. This is plastic that will no longer end up in our marine environment. So the robot supports Aarhus Municipality’s sustainability efforts and above all, the UN’s global sustainable development goal no. 14: Life Below Water,” said Kim Gulvad Svendsen.
Every year, the amount of plastic waste that ends in the oceans is equivalent in weight to 57,000 blue whales. At least 90% of the plastic waste that floats around in the oceans, ends in the sea via river systems, according to the periodical Environmental Science.
“Once waste enters the sea it spreads quickly and is difficult to collect. Whereas the current in a river allows for the systematic filtering of waste in a limited area without disturbing fish or birds,” said Peter Grønkjær, Professor of Marine Biology at the Aarhus University.
Mads Tranders Nielsen from All In On Green is the man who invented SeaProtectorOne.
“In an ideal world, every citizen everywhere would learn to always put waste into a waste bin. But we don’t live in an ideal world. The idea for the robot came to me when I saw huge amounts of waste floating in a river in Melbourne. SeaProtectorOne has now shown its worth, even in Aarhus, one of Europe’s greenest cities. So, I’m looking forward to bringing this technology to the rest of the world for the benefit of the marine environment, fish and birds,” said Mads Tranders Nielsen from All In On Green.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221211005006/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom